Frank McCormick, PhD, FRS
Adjunct Professor
HDF Comprehensive Cancer Ctr
School of Medicine

Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. In addition, Dr. McCormick’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Dr. McCormick's current research interests center on ways of targeting Ras proteins and their regulators, including the NF1 protein neurofibromin.

Dr. McCormick was Director of the Helen Diller Family Comprehensive Cancer Center from 1997 to 2014 and he served as President, 2012-2013, for the American Association for Cancer Research. Since 2013, Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers.

Dr. McCormick is the author of over 400 scientific publications and holds more than 20 issued patents and is a Fellow of the Royal Society and a member of the National Academy of Sciences.

• Structural dynamics of RAF1-HSP90-CDC37 and HSP90 complexes reveal asymmetric client interactions and key structural elements.
  Communications biology 2024 Finci LI, Chakrabarti M, Gulten G, Finney J, Grose C, Fox T, Yang R, Nissley DV, McCormick F, Esposito D, Balius TE, Simanshu DK
• Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
  Science advances 2024 Whitley MJ, Tran TH, Rigby M, Yi M, Dharmaiah S, Waybright TJ, Ramakrishnan N, Perkins S, Taylor T, Messing S, Esposito D, Nissley DV, McCormick F, Stephen AG, Turbyville T, Cornilescu G, Simanshu DK
• Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR.
  The Journal of biological chemistry 2024 Sharma AK, Pei J, Yang Y, Dyba M, Smith B, Rabara D, Larsen EK, Lightstone FC, Esposito D, Stephen AG, Wang B, Beltran PJ, Wallace E, Nissley DV, McCormick F, Maciag AE
• Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.
  Nature communications 2024 Vasudevan HN, Payne E, Delley CL, John Liu S, Mirchia K, Sale MJ, Lastella S, Nunez MS, Lucas CG, Eaton CD, Casey-Clyde T, Magill ST, Chen WC, Braunstein SE, Perry A, Jacques L, Reddy AT, Pekmezci M, …
• Determining KRAS4B-Targeting Compound Specificity by Top-Down Mass Spectrometry.
  Methods in molecular biology (Clifton, N.J.) 2024 D'Ippolito RA, Scheidemantle GM, Rabara D, Abreu Blanco M, Ramakrishnan N, Widmeyer SRT, Messing S, Turner D, Maciag AE, Stephen AG, Esposito D, McCormick F, Nissley DV, DeHart CJ
• Progress in Targeting KRAS Directly.
  Methods in molecular biology (Clifton, N.J.) 2024 Nissley DV, Stephen AG, Yi M, McCormick F
• Long-term ecological research in freshwaters enabled by regional biodiversity collections, stable isotope analysis, and environmental informatics.
  Bioscience 2023 Turner TF, Bart HL, McCormick F, Besser AC, Bowes RE, Capps KA, DeArmon ES, Dillman CB, Driscoll KP, Dugger A, Hamilton GL, Harris PM, Hendrickson DA, Hoffman J, Knouft JH, Lepak RF, López-Fernández H…
• RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.
  Science advances 2023 Cuevas-Navarro A, Wagner M, Van R, Swain M, Mo S, Columbus J, Allison MR, Cheng A, Messing S, Turbyville TJ, Simanshu DK, Sale MJ, McCormick F, Stephen AG, Castel P
• Reduced dynamic complexity allows structure elucidation of an excited state of KRASG13D.
  Communications biology 2023 Chao FA, Chan AH, Dharmaiah S, Schwieters CD, Tran TH, Taylor T, Ramakrishnan N, Esposito D, Nissley DV, McCormick F, Simanshu DK, Cornilescu G
• RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
  The Journal of investigative dermatology 2023 Rhodes SD, McCormick F, Cagan RL, Bakker A, Staedtke V, Ly I, Steensma MR, Lee SY, Romo CG, Blakeley JO, Sarin KY
• The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling.
  The Journal of biological chemistry 2023 Lopez J, Bonsor DA, Sale MJ, Urisman A, Mehalko JL, Cabanski-Dunning M, Castel P, Simanshu DK, McCormick F
• Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.
  Proceedings of the National Academy of Sciences of the United States of America 2023 Young LC, Goldstein de Salazar R, Han SW, Huang ZYS, Merk A, Drew M, Darling J, Wall V, Grisshammer R, Cheng A, Allison MR, Sale MJ, Nissley DV, Esposito D, Ognjenovic J, McCormick F
• Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.
  Cancer discovery 2022 Chen S, Vedula RS, Cuevas-Navarro A, Lu B, Hogg SJ, Wang E, Benbarche S, Knorr K, Kim WJ, Stanley RF, Cho H, Erickson C, Singer M, Cui D, Tittley S, Durham BH, Pavletich TS, Fiala E, Walsh MF, Inoue D…
• Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome.
  Nature structural & molecular biology 2022 Bonsor DA, Alexander P, Snead K, Hartig N, Drew M, Messing S, Finci LI, Nissley DV, McCormick F, Esposito D, Rodriguez-Viciana P, Stephen AG, Simanshu DK
• Novel Regulators of Macropinocytosis-Dependent Growth Revealed by Informer Set Library Screening in Pancreatic Cancer Cells.
  Metabolites 2022 Kim SH, Song JH, Kim MJ, Song MG, Ku AA, Bandyopadhyay S, McCormick F, Kim SE
• Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.
  Nature 2022 Kwon JJ, Hajian B, Bian Y, Young LC, Amor AJ, Fuller JR, Fraley CV, Sykes AM, So J, Pan J, Baker L, Lee SJ, Wheeler DB, Mayhew DL, Persky NS, Yang X, Root DE, Barsotti AM, Stamford AW, Perry CK, …
• ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.
  Molecular cell 2022 Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, Merna Timaul N, Hechtman J, Paroder V, Lin M, Mattar M, Qiu J, Chang Q, Zhao H, Zhang J, Little M, Adachi Y, Han SW, Taylor BS, Ebi H, Abdel-Wahab O, de…
• Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs.
  eLife 2022 Cuevas-Navarro A, Rodriguez-Muñoz L, Grego-Bessa J, Cheng A, Rauen KA, Urisman A, McCormick F, Jimenez G, Castel P
• Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
  Blood advances 2022 Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, Ai WZ
• More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022 Lietman CD, Johnson ML, McCormick F, Lindsay CR
• RAS at 40: Update from the RAS Initiative.
  Cancer discovery 2022 Nissley DV, McCormick F
• Insights into the Cross Talk between Effector and Allosteric Lobes of KRAS from Methyl Conformational Dynamics.
  Journal of the American Chemical Society 2022 Chao FA, Dharmaiah S, Taylor T, Messing S, Gillette W, Esposito D, Nissley DV, McCormick F, Byrd RA, Simanshu DK, Cornilescu G
• Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors.
  Proceedings of the National Academy of Sciences of the United States of America 2022 Lai LP, Fer N, Burgan W, Wall VE, Xu B, Soppet D, Esposito D, Nissley DV, McCormick F
• Machine learning-driven multiscale modeling reveals lipid-dependent dynamics of RAS signaling proteins.
  Proceedings of the National Academy of Sciences of the United States of America 2022 Ingólfsson HI, Neale C, Carpenter TS, Shrestha R, López CA, Tran TH, Oppelstrup T, Bhatia H, Stanton LG, Zhang X, Sundram S, Di Natale F, Agarwal A, Dharuman G, Kokkila Schumacher SIL, Turbyville T, …
• Cost Structures of US Organ Procurement Organizations.
  Transplantation 2021 Held PJ, Bragg-Gresham JL, Peters TG, McCormick F, Chertow G, Vaughan WP, Roberts JP
• NMR 1H, 13C, 15N backbone resonance assignments of the T35S and oncogenic T35S/Q61L mutants of human KRAS4b in the active, GppNHp-bound conformation.
  Biomolecular NMR assignments 2021 Sharma AK, Dyba M, Tonelli M, Smith B, Gillette WK, Esposito D, Nissley DV, McCormick F, Maciag AE
• A brief history of RAS and the RAS Initiative.
  Advances in cancer research 2021 McCormick F
• RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.
  Proceedings of the National Academy of Sciences of the United States of America 2021 Castel P, Dharmaiah S, Sale MJ, Messing S, Rizzuto G, Cuevas-Navarro A, Cheng A, Trnka MJ, Urisman A, Esposito D, Simanshu DK, McCormick F
• UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.
  Proceedings of the National Academy of Sciences of the United States of America 2021 Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F, Kim SE
• Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
  Blood cancer discovery 2021 Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye…
• A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness.
  Frontiers in cell and developmental biology 2021 Okutachi S, Manoharan GB, Kiriazis A, Laurini C, Catillon M, McCormick F, Yli-Kauhaluoma J, Abankwa D
• The RAS GTPase RIT1 compromises mitotic fidelity through spindle assembly checkpoint suppression.
  Current biology : CB 2021 Cuevas-Navarro A, Van R, Cheng A, Urisman A, Castel P, McCormick F
• Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.
  Cell reports methods 2021 Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez…
• Estimated impact of novel coronavirus-19 and transplant center inactivity on end-stage renal disease-related patient mortality in the United States.
  Clinical transplantation 2021 Peters TG, Bragg-Gresham JL, Klopstock AC, Roberts JP, Chertow G, McCormick F, Held PJ
• RAS-targeted therapies.
  Nature reviews. Drug discovery 2021 Moore AR, Rosenberg SC, McCormick F, Malek S
• Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition.
  SLAS discovery : advancing life sciences R & D 2021 Lai LP, Brel V, Sharma K, Frappier J, Le-Henanf N, Vivet B, Muzet N, Schell E, Morales R, Rooney E, Basse N, Yi M, Lacroix F, Holderfield M, Englaro W, Marcireau C, Debussche L, Nissley DV, McCormick …
• Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.
  Nature genetics 2021 Inoue D, Polaski JT, Taylor J, Castel P, Chen S, Kobayashi S, Hogg SJ, Hayashi Y, Pineda JMB, El Marabti E, Erickson C, Knorr K, Fukumoto M, Yamazaki H, Tanaka A, Fukui C, Lu SX, Durham BH, Liu B, …
• The Metabolic Landscape of RAS-Driven Cancers from biology to therapy.
  Nature cancer 2021 Mukhopadhyay S, Vander Heiden MG, McCormick F
• Correction: DoMY-Seq: A yeast two-hybrid-based technique for precision mapping of protein-protein interaction motifs.
  The Journal of biological chemistry 2021 Castel P, Holtz-Morris A, Kwon Y, Suter BP, McCormick F
• KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation.
  Nature communications 2021 Tran TH, Chan AH, Young LC, Bindu L, Neale C, Messing S, Dharmaiah S, Taylor T, Denson JP, Esposito D, Nissley DV, Stephen AG, McCormick F, Simanshu DK
• Author Correction: RAS-targeted therapies: is the undruggable drugged?
  Nature reviews. Drug discovery 2020 Moore AR, Rosenberg SC, McCormick F, Malek S
• Reducing the Shortage of Transplant Kidneys: A Lost Opportunity for the US Health Resources and Services Administration (HRSA).
  American journal of kidney diseases : the official journal of the National Kidney Foundation 2020 McCormick F, Held PJ, Chertow GM, Peters TG, Roberts JP
• DoMY-Seq: A yeast two-hybrid-based technique for precision mapping of protein-protein interaction motifs.
  The Journal of biological chemistry 2020 Castel P, Holtz-Morris A, Kwon Y, Suter BP, McCormick F
• SPRED proteins and their roles in signal transduction, development, and malignancy.
  Genes & development 2020 Lorenzo C, McCormick F
• Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway.
  Molecular systems biology 2020 Gillies TE, Pargett M, Silva JM, Teragawa CK, McCormick F, Albeck JG
• Uncovering a membrane-distal conformation of KRAS available to recruit RAF to the plasma membrane.
  Proceedings of the National Academy of Sciences of the United States of America 2020 Van QN, López CA, Tonelli M, Taylor T, Niu B, Stanley CB, Bhowmik D, Tran TH, Frank PH, Messing S, Alexander P, Scott D, Ye X, Drew M, Chertov O, Lösche M, Ramanathan A, Gross ML, Hengartner NW, …
• The molecular functions of RIT1 and its contribution to human disease.
  The Biochemical journal 2020 Van R, Cuevas-Navarro A, Castel P, McCormick F
• Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
  Cell reports 2020 Yan W, Markegard E, Dharmaiah S, Urisman A, Drew M, Esposito D, Scheffzek K, Nissley DV, McCormick F, Simanshu DK
• Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
  The Journal of investigative dermatology 2020 Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ
• ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications.
  Scientific reports 2020 Yi M, Nissley DV, McCormick F, Stephens RM
• RAS-targeted therapies: is the undruggable drugged?
  Nature reviews. Drug discovery 2020 Moore AR, Rosenberg SC, McCormick F, Malek S
• Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.
  Nature communications 2020 Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S
• The duality of human oncoproteins: drivers of cancer and congenital disorders.
  Nature reviews. Cancer 2020 Castel P, Rauen KA, McCormick F
• The small molecule BI-2852 induces a nonfunctional dimer of KRAS.
  Proceedings of the National Academy of Sciences of the United States of America 2020 Tran TH, Alexander P, Dharmaiah S, Agamasu C, Nissley DV, McCormick F, Esposito D, Simanshu DK, Stephen AG, Balius TE
• Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior.
  eLife 2020 Goswami D, Yang Y, Gudla PR, Columbus J, Worthy K, Rigby M, Wheeler M, Mukhopadhyay S, Powell K, Burgan W, Wall V, Esposito D, Simanshu DK, Lightstone FC, Nissley DV, McCormick F, Turbyville T
• Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.
  Cancer cell 2020 McCormick F
• Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
  American journal of medical genetics. Part A 2020 Gross AM, Frone M, Gripp KW, Gelb BD, Schoyer L, Schill L, Stronach B, Biesecker LG, Esposito D, Hernandez ER, Legius E, Loh ML, Martin S, Morrison DK, Rauen KA, Wolters PL, Zand D, McCormick F, …
• Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
  Cancer research 2020 Mukhopadhyay S, Goswami D, Adiseshaiah PP, Burgan W, Yi M, Guerin TM, Kozlov SV, Nissley DV, McCormick F
• Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.
  The Journal of biological chemistry 2019 Sherekar M, Han SW, Ghirlando R, Messing S, Drew M, Rabara D, Waybright T, Juneja P, O'Neill H, Stanley CB, Bhowmik D, Ramanathan A, Subramaniam S, Nissley DV, Gillette W, McCormick F, Esposito D
• The sixth international RASopathies symposium: Precision medicine-From promise to practice.
  American journal of medical genetics. Part A 2019 Gripp KW, Schill L, Schoyer L, Stronach B, Bennett AM, Blaser S, Brown A, Burdine R, Burkitt-Wright E, Castel P, Darilek S, Dias A, Dyer T, Ellis M, Erickson G, Gelb BD, Green T, Gross A, Ho A, Holder…
• The cost of procuring deceased donor kidneys: Evidence from OPO cost reports 2013-2017.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019 Held PJ, Bragg-Gresham JL, Peters T, Chertow GM, McCormick F, Roberts JP
• Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus L, Wieduwilt MJ, William BM, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer JE, Ai WZ
• KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
  Proceedings of the National Academy of Sciences of the United States of America 2019 Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M
• Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, McCormick F
• Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder.
  Proceedings of the National Academy of Sciences of the United States of America 2019 Donohue E, Khorsand S, Mercado G, Varney KM, Wilder PT, Yu W, MacKerell AD, Alexander P, Van QN, Moree B, Stephen AG, Weber DJ, Salafsky J, McCormick F
• Removing Disincentives to Kidney Donation: A Quantitative Analysis.
  Journal of the American Society of Nephrology : JASN 2019 McCormick F, Held PJ, Chertow GM, Peters TG, Roberts JP
• Structures of N-terminally processed KRAS provide insight into the role of N-acetylation.
  Scientific reports 2019 Dharmaiah S, Tran TH, Messing S, Agamasu C, Gillette WK, Yan W, Waybright T, Alexander P, Esposito D, Nissley DV, McCormick F, Stephen AG, Simanshu DK
• Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
  Nature communications 2019 Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F
• Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.
  Gene therapy 2019 Bai RY, Esposito D, Tam AJ, McCormick F, Riggins GJ, Wade Clapp D, Staedtke V
• RIT1 oncoproteins escape LZTR1-mediated proteolysis.
  Science (New York, N.Y.) 2019 Castel P, Cheng A, Cuevas-Navarro A, Everman DB, Papageorge AG, Simanshu DK, Tankka A, Galeas J, Urisman A, McCormick F
• KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner.
  Biophysical journal 2019 Agamasu C, Ghirlando R, Taylor T, Messing S, Tran TH, Bindu L, Tonelli M, Nissley DV, McCormick F, Stephen AG
• MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.
  Proceedings of the National Academy of Sciences of the United States of America 2019 Lee CS, Lee LC, Yuan TL, Chakka S, Fellmann C, Lowe SW, Caplen NJ, McCormick F, Luo J
• Progress in targeting RAS with small molecule drugs.
  The Biochemical journal 2019 McCormick F
• Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane.
  The Journal of biological chemistry 2018 Lakshman B, Messing S, Schmid EM, Clogston JD, Gillette WK, Esposito D, Kessing B, Fletcher DA, Nissley DV, McCormick F, Stephen AG, Jean-Francois FL
• Would government compensation of living kidney donors exploit the poor? An empirical analysis.
  PloS one 2018 Held PJ, McCormick F, Chertow GM, Peters TG, Roberts JP
• Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
  Nature medicine 2018 Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, …
• The Terrible Toll of the Kidney Shortage.
  Journal of the American Society of Nephrology : JASN 2018 McCormick F, Held PJ, Chertow GM
• SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
  Proceedings of the National Academy of Sciences of the United States of America 2018 Young LC, Hartig N, Boned Del Río I, Sari S, Ringham-Terry B, Wainwright JR, Jones GG, McCormick F, Rodriguez-Viciana P
• Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
  American journal of medical genetics. Part A 2018 Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B…
• Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.
  Oncotarget 2018 Ye X, Luke BT, Wei BR, Kaczmarczyk JA, Loncarek J, Dwyer JE, Johann DJ, Saul RG, Nissley DV, McCormick F, Whiteley GR, Blonder J
• Oncogenic Signaling Pathways in The Cancer Genome Atlas.
  Cell 2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, …
• Differential Effector Engagement by Oncogenic KRAS.
  Cell reports 2018 Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, Fer N, Strathern LA, Powell K, Smith B, Waters AM, Drubin D, Thomson T, Liao R, Greninger P, Stein GT, Murchie E, Cortez E, Egan RK, Procter L,…
• c-Raf in KRas Mutant Cancers: A Moving Target.
  Cancer cell 2018 McCormick F
• Dual gene activation and knockout screen reveals directional dependencies in genetic networks.
  Nature biotechnology 2018 Boettcher M, Tian R, Blau JA, Markegard E, Wagner RT, Wu D, Mo X, Biton A, Zaitlen N, Fu H, McCormick F, Kampmann M, McManus MT
• Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality.
  Nature communications 2017 Kitagawa M, Liao PJ, Lee KH, Wong J, Shang SC, Minami N, Sampetrean O, Saya H, Lingyun D, Prabhu N, Diam GK, Sobota R, Larsson A, Nordlund P, McCormick F, Ghosh S, Epstein DM, Dymock BW, Lee SH
• Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.
  Nature 2017 Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, McCormick F, McManus MT
• Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.
  Science signaling 2017 Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der…
• RAS Proteins and Their Regulators in Human Disease.
  Cell 2017 Simanshu DK, Nissley DV, McCormick F
• Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras.
  ACS chemical biology 2017 Novotny CJ, Hamilton GL, McCormick F, Shokat KM
• Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes.
  Cancer informatics 2017 Stephens RM, Yi M, Kessing B, Nissley DV, McCormick F
• ETS-targeted therapy: can it substitute for MEK inhibitors?
  Clinical and translational medicine 2017 Tetsu O, McCormick F
• Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient.
  Oral oncology 2017 Wang SJ, Asthana S, van Zante A, Heaton CM, Phuchareon J, Stein L, Higuchi S, Kishimoto T, Chiu CY, Olshen AB, McCormick F, Tetsu O
• Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface.
  Oncotarget 2016 Ye X, Chan KC, Waters AM, Bess M, Harned A, Wei BR, Loncarek J, Luke BT, Orsburn BC, Hollinger BD, Stephens RM, Bagni R, Martinko A, Wells JA, Nissley DV, McCormick F, Whiteley G, Blonder J
• Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
  Proceedings of the National Academy of Sciences of the United States of America 2016 Dharmaiah S, Bindu L, Tran TH, Gillette WK, Frank PH, Ghirlando R, Nissley DV, Esposito D, McCormick F, Stephen AG, Simanshu DK
• The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
  Proceedings of the National Academy of Sciences of the United States of America 2016 Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K
• The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.
  American journal of medical genetics. Part A 2016 Stevenson DA, Schill L, Schoyer L, Andresen BS, Bakker A, Bayrak-Toydemir P, Burkitt-Wright E, Chatfield K, Elefteriou F, Elgersma Y, Fisher MJ, Franz D, Gelb BD, Goriely A, Gripp KW, Hardan AY, …
• K-Ras protein as a drug target.
  Journal of molecular medicine (Berlin, Germany) 2016 McCormick F
• Drug Resistance to EGFR Inhibitors in Lung Cancer.
  Chemotherapy 2016 Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F
• ABO-Incompatible Kidney Transplants: Twice as Expensive, Half as Good.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2016 Held PJ, McCormick F
• K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling.
  Cell 2015 Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F
• Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions.
  Scientific reports 2015 Gillette WK, Esposito D, Abreu Blanco M, Alexander P, Bindu L, Bittner C, Chertov O, Frank PH, Grose C, Jones JE, Meng Z, Perkins S, Van Q, Ghirlando R, Fivash M, Nissley DV, McCormick F, Holderfield …
• AKT inactivation causes persistent drug tolerance to EGFR inhibitors.
  Pharmacological research 2015 Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ, McCormick F
• A Cost-Benefit Analysis of Government Compensation of Kidney Donors.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015 Held PJ, McCormick F, Ojo A, Roberts JP
• ETS1 inactivation causes innate drug resistance to EGFR inhibitors.
  Molecular & cellular oncology 2015 Tetsu O, Phuchareon J, Eisele DW, McCormick F
• EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
  Proceedings of the National Academy of Sciences of the United States of America 2015 Phuchareon J, McCormick F, Eisele DW, Tetsu O
• Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.
  Proceedings of the National Academy of Sciences of the United States of America 2015 Nan X, Tamgüney TM, Collisson EA, Lin LJ, Pitt C, Galeas J, Lewis S, Gray JW, McCormick F, Chu S
• Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions.
  Cancer research 2015 Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F
• KRAS as a Therapeutic Target.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 McCormick F
• The potential of targeting Ras proteins in lung cancer.
  Expert opinion on therapeutic targets 2015 McCormick F
• Resistance to EGFR-targeted therapy by Ets-1 inactivation.
  Cell cycle (Georgetown, Tex.) 2015 Tetsu O, Eisele DW, McCormick F
• Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.
  Cancer discovery 2014 Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat …
• Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance.
  Translational oncology 2014 Phuchareon J, Overdevest JB, McCormick F, Eisele DW, van Zante A, Tetsu O
• Social interactomes for enabling research communities.
  Cancer discovery 2014 Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F
• c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands.
  Translational oncology 2014 Phuchareon J, van Zante A, Overdevest JB, McCormick F, Eisele DW, Tetsu O
• Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
  Cell reports 2014 Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM
• Development of siRNA payloads to target KRAS-mutant cancer.
  Cancer discovery 2014 Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW
• Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
  Nature reviews. Cancer 2014 Holderfield M, Deuker MM, McCormick F, McMahon M
• Unicompartmental knee arthroplasty versus high tibial osteotomy: United States practice patterns for the surgical treatment of unicompartmental arthritis.
  The Journal of arthroplasty 2014 Nwachukwu BU, McCormick FM, Schairer WW, Frank RM, Provencher MT, Roche MW
• Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication.
  Cell metabolism 2014 Thai M, Graham NA, Braas D, Nehil M, Komisopoulou E, Kurdistani SK, McCormick F, Graeber TG, Christofk HR
• Dragging ras back in the ring.
  Cancer cell 2014 Stephen AG, Esposito D, Bagni RK, McCormick F
• Current status of evidence-based sports medicine.
  Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 2014 Harris JD, Cvetanovich G, Erickson BJ, Abrams GD, Chahal J, Gupta AK, McCormick FM, Bach BR
• Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
  Cancer research 2014 Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D
• Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
  PloS one 2014 Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, …
• Functional Performance Testing After Anterior Cruciate Ligament Reconstruction: A Systematic Review.
  Orthopaedic journal of sports medicine 2014 Abrams GD, Harris JD, Gupta AK, McCormick FM, Bush-Joseph CA, Verma NN, Cole BJ, Bach BR
• CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
  American journal of medical genetics. Part A 2014 Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann…
• Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.
  Cancer discovery 2013 Salt MB, Bandyopadhyay S, McCormick F
• High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A.
  Oncogene 2013 Nehil M, Paquette J, Tokuyasu T, McCormick F
• Killing tumors by keeping ras and PI3' kinase apart.
  Cancer cell 2013 Yuan TL, McCormick F
• Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling.
  Proceedings of the National Academy of Sciences of the United States of America 2013 Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S
• Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
  Cancer cell 2013 Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW
• MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells.
  Proceedings of the National Academy of Sciences of the United States of America 2013 Lyons J, Bastian BC, McCormick F
• RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
  Cancer cell 2013 Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE
• An assessment of the quality of rotator cuff randomized controlled trials: utilizing the Jadad score and CONSORT criteria.
  Journal of shoulder and elbow surgery 2013 McCormick F, Cvetanovich GL, Kim JM, Harris JD, Gupta AK, Abrams GD, Romeo AA, Provencher MT
• Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.
  Cancer discovery 2012 Young A, Lou D, McCormick F
• A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
  Genes & development 2012 Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F
• Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
  PloS one 2012 Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, …
• Cancer therapy based on oncogene addiction.
  Journal of surgical oncology 2011 McCormick F
• Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
  American journal of medical genetics. Part C, Seminars in medical genetics 2011 Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH
• Promoting growth for preterm infants following hospital discharge.
  Archives of disease in childhood. Fetal and neonatal edition 2011 Morgan JA, Young L, McCormick FM, McGuire W
• Therapeutic strategies for targeting ras proteins.
  Genes & cancer 2011 Gysin S, Salt M, Young A, McCormick F
• Mutant onco-proteins as drug targets: successes, failures, and future prospects.
  Current opinion in genetics & development 2011 McCormick F
• Mad2 inhibits the mitotic kinesin MKlp2.
  The Journal of cell biology 2010 Lee SH, McCormick F, Saya H
• Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions.
  Gene therapy 2010 van Zeeburg HJ, Huizenga A, Brink A, van den Doel PB, Zhu ZB, McCormick F, Brakenhoff RH, van Beusechem VW
• Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells.
  Virology journal 2010 Lyle C, McCormick F
• Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.
  Cancer cell 2010 Ishida S, McCormick F, Smith-McCune K, Hanahan D
• The molecular pathology of cancer.
  Nature reviews. Clinical oncology 2010 Harris TJ, McCormick F
• The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast and ETEA in humans.
  Molecular and cellular biology 2010 Phan VT, Ding VW, Li F, Chalkley RJ, Burlingame A, McCormick F
• What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.
  American journal of medical genetics. Part A 2010 Kissil JL, Blakeley JO, Ferner RE, Huson SM, Kalamarides M, Mautner VF, McCormick F, Morrison H, Packer R, Ramesh V, Ratner N, Rauen KA, Stevenson DA, Hunter-Schaedle K, North K
• How blocking Raf activates the MAPK pathway.
  Pigment cell & melanoma research 2010 McCormick F
• Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
  Oncogene 2010 Murayama-Hosokawa S, Oda K, Nakagawa S, Ishikawa S, Yamamoto S, Shoji K, Ikeda Y, Uehara Y, Fukayama M, McCormick F, Yano T, Taketani Y, Aburatani H
• Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
  American journal of medical genetics. Part A 2010 Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, …
• EGFR signals to mTOR through PKC and independently of Akt in glioma.
  Science signaling 2009 Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA
• Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
  Cancer research 2009 Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ,…
• Ras signaling and therapies.
  Advances in cancer research 2009 Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F
• Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint.
  Genes & development 2008 Lee SH, Sterling H, Burlingame A, McCormick F
• PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
  Cancer research 2008 Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F
• DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight.
  Nucleic acids research 2008 Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi GN, McCormick F, Jones PA, Laird PW
• Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
  Leukemia 2008 Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP
• E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
  Oncogene 2008 Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F
• An analysis of the rotator interval in patients with anterior, posterior, and multidirectional shoulder instability.
  Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 2008 Provencher MT, Dewing CB, Bell SJ, McCormick F, Solomon DJ, Rooney TB, Stanley M
• Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007.
  American journal of medical genetics. Part A 2008 Rauen KA, Hefner E, Carrillo K, Taylor J, Messier L, Aoki Y, Gripp KW, Matsubara Y, Proud VK, Hammond P, Allanson JE, Delrue MA, Axelrad ME, Lin AE, Doyle DA, Kerr B, Carey JC, McCormick F, Silva AJ, …
• Combinatorial patterns of somatic gene mutations in cancer.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008 Yeang CH, McCormick F, Levine A
• Skp2 suppresses p53-dependent apoptosis by inhibiting p300.
  Molecular cell 2008 Kitagawa M, Lee SH, McCormick F
• An analysis of capsular area in patients with anterior, posterior, and multidirectional shoulder instability.
  The American journal of sports medicine 2008 Dewing CB, McCormick F, Bell SJ, Solomon DJ, Stanley M, Rooney TB, Provencher MT
• Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
  PloS one 2007 Estep AL, Palmer C, McCormick F, Rauen KA
• Polycystic kidneys: a cautionary story.
  The British journal of radiology 2007 Currie RJ, Freeman SJ, McCormick F, McGonigle RJ
• Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
  Human molecular genetics 2007 Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O
• Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.
  Journal of the National Cancer Institute 2007 Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J
• Success and failure on the ras pathway.
  Cancer biology & therapy 2007 McCormick F
• Critical role for arginine methylation in adenovirus-infected cells.
  Journal of virology 2007 Iacovides DC, O'Shea CC, Oses-Prieto J, Burlingame A, McCormick F
• Activation of p53 by Dishevelled independent of Wnt or planar polarity pathways.
  Journal of molecular medicine (Berlin, Germany) 2007 Ding VW, Lin LP, Chiang AL, McCormick F
• A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation.
  PloS one 2006 Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
  Cancer cell 2006 Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM…
• p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins.
  The EMBO journal 2006 Lee SH, McCormick F
• Oncolytic adenoviruses as antiglioma agents.
  Expert review of anticancer therapy 2006 Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J
• A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.
  Molecular cell 2006 Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F
• Ras ubiquitination: coupling spatial sorting and signal transmission.
  Cancer cell 2006 Rodriguez-Viciana P, McCormick F
• Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
  Science (New York, N.Y.) 2006 Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA
• Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J
• Characterization of interactions between ras family GTPases and their effectors.
  Methods in enzymology 2006 Rodriguez-Viciana P, McCormick F
• Wnt-1 signal as a potential cancer therapeutic target.
  Drug news & perspectives 2006 You L, Kim J, He B, Xu Z, McCormick F, Jablons DM
• High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
  Cancer research 2005 Oda K, Stokoe D, Taketani Y, McCormick F
• Future prospects for oncolytic therapy.
  Oncogene 2005 McCormick F
• Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis.
  Oncogene 2005 Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM
• A conditional feedback loop regulates Ras activity through EphA2.
  Cancer cell 2005 Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F
• Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.
  Cancer gene therapy 2005 Reid TR, Freeman S, Post L, McCormick F, Sze DY
• Adenovirus overrides cellular checkpoints for protein translation.
  Cell cycle (Georgetown, Tex.) 2005 O'Shea CC, Choi S, McCormick F, Stokoe D
• Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.
  Cancer cell 2005 O'Shea CC, Soria C, Bagus B, McCormick F
• Killing time for cancer cells.
  Nature reviews. Cancer 2005 Klein S, McCormick F, Levitzki A
• Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.
  Oncogene 2005 He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM
• Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication.
  The EMBO journal 2005 O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, Shen J, McCormick F, Stokoe D
• RalGDS comes of age.
  Cancer cell 2005 Rodriguez-Viciana P, McCormick F
• Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
  Cancer research 2005 He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM
• Cancer targets in the Ras pathway.
  Cold Spring Harbor symposia on quantitative biology 2005 Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F
• Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells.
  Journal of molecular medicine (Berlin, Germany) 2004 Lee SH, McCormick F
• Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.
  Cancer cell 2004 O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F
• Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells.
  The Journal of biological chemistry 2004 Brandts CH, Bilanges B, Hare G, McCormick F, Stokoe D
• Activation of the hedgehog pathway in advanced prostate cancer.
  Molecular cancer 2004 Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J
• Cloning and characterization of the promoter of human Wnt inhibitory factor-1.
  Biochemical and biophysical research communications 2004 Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F, Jablons DM
• Role for PP2A in ARF signaling to p53.
  Proceedings of the National Academy of Sciences of the United States of America 2004 Moule MG, Collins CH, McCormick F, Fried M
• Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma.
  Oncogene 2004 Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM
• Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.
  Oncogene 2004 You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM
• An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.
  Cancer research 2004 You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM
• Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
  Cancer research 2004 Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM
• Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate.
  Molecular and cellular biology 2004 Rodriguez-Viciana P, Sabatier C, McCormick F
• Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells.
  Cancer research 2004 You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F, Jablons DM
• Cancer: survival pathways meet their end.
  Nature 2004 McCormick F
• A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells.
  Neoplasia (New York, N.Y.) 2004 He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM
• Future directions: oncolytic viruses.
  Clinical lung cancer 2004 You L, He B, Xu Z, McCormick F, Jablons DM
• Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation.
  Genes & development 2003 Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, Aranda S, Palomo S, McCormick F, Izpisúa-Belmonte JC, de la Pompa JL
• SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2003 He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM
• Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.
  Oncogene 2003 Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM
• Chromosome aberrations in solid tumors.
  Nature genetics 2003 Albertson DG, Collins C, McCormick F, Gray JW
• Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.
  Cancer research 2003 Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F, Jablons DM
• Cancer-specific viruses and the development of ONYX-015.
  Cancer biology & therapy 2003 McCormick F
• Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q.
  Anticancer research 2003 Jensen RH, Tiirikainen M, You L, Ginzinger D, He B, Uematsu K, Xu Z, Treseler P, McCormick F, Jablons DM
• Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.
  Cancer research 2003 Anders M, Christian C, McMahon M, McCormick F, Korn WM
• Proliferation of cancer cells despite CDK2 inhibition.
  Cancer cell 2003 Tetsu O, McCormick F
• Cloning and characterization of a functional promoter of the human SOCS-3 gene.
  Biochemical and biophysical research communications 2003 He B, You L, Uematsu K, Matsangou M, Xu Z, He M, McCormick F, Jablons DM
• Phosphorylation of p16INK4A correlates with Cdk4 association.
  The Journal of biological chemistry 2003 Gump J, Stokoe D, McCormick F
• A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells.
  Anticancer research 2003 Yang CT, You L, Lin YC, Lin CL, Mccormick F, Jablons DM
• The RB and p53 pathways in cancer.
  Cancer cell 2002 Sherr CJ, McCormick F
• Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy.
  Cancer research 2002 Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD, McCormick F
• Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
  Molecular cancer therapeutics 2002 Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM
• MDMX inhibits the p300/CBP-mediated acetylation of p53.
  DNA and cell biology 2002 Sabbatini P, McCormick F
• Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents.
  Cancer cell 2002 Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A
• Replication-selective viruses for cancer therapy.
  Journal of molecular medicine (Berlin, Germany) 2001 Biederer C, Ries S, Brandts CH, McCormick F
• Cancer gene therapy: fringe or cutting edge?
  Nature reviews. Cancer 2001 McCormick F
• p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.
  Cancer research 2001 Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM
• Method for screening ecdysone-inducible stable cell lines.
  BioTechniques 2001 Wakita K, McCormick F, Tetsu O
• A role of PDGFRalpha in basal cell carcinoma proliferation.
  Proceedings of the National Academy of Sciences of the United States of America 2001 Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F
• New-age drug meets resistance.
  Nature 2001 McCormick F
• Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells.
  Cancer research 2001 Chen RH, McCormick F
• Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells.
  Oncogene 2001 Yount GL, Afshar G, Ries S, Korn M, Shalev N, Basila D, McCormick F, Haas-Kogan DA
• ErbB receptors and Ras: upstream, downstream?
  Cancer journal (Sudbury, Mass.) 2001 Park JW, McCormick F
• A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics.
  Cancer research 2001 Wakita K, Tetsu O, McCormick F
• ONYX-015 selectivity and the p14ARF pathway.
  Oncogene 2000 McCormick F
• Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.
  Seminars in cancer biology 2000 McCormick F
• Small-molecule inhibitors of cell signaling.
  Current opinion in biotechnology 2000 McCormick F
• Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling.
  The Journal of biological chemistry 2000 Ding VW, Chen RH, McCormick F
• Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.
  Cell 2000 Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F
• Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).
  Nature medicine 2000 Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM
• The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development.
  The Journal of biological chemistry 2000 Biederer CH, Ries SJ, Moser M, Florio M, Israel MA, McCormick F, Buettner R
• Regulation of Tiam1 nucleotide exchange activity by pleckstrin domain binding ligands.
  The Journal of biological chemistry 2000 Crompton AM, Foley LH, Wood A, Roscoe W, Stokoe D, McCormick F, Symons M, Bollag G
• Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C.
  The Journal of biological chemistry 2000 Chen RH, Ding WV, McCormick F
• Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells.
  Journal of the National Cancer Institute 2000 Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM
• Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling.
  Molecular cell 2000 Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS
• Signalling networks that cause cancer.
  Trends in cell biology 1999 McCormick F
• Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 1999 Srinivasan R, Benton E, McCormick F, Thomas H, Gullick WJ
• Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis.
  The Journal of biological chemistry 1999 Sabbatini P, McCormick F
• Cancer therapy based on p53.
  The cancer journal from Scientific American 1999 McCormick F
• Brefeldin A: the advantage of being uncompetitive.
  Cell 1999 Chardin P, McCormick F
• Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.
  Nature 1999 Tetsu O, McCormick F
• A frequent activated smoothened mutation in sporadic basal cell carcinomas.
  Oncogene 1999 Lam CW, Xie J, To KF, Ng HK, Lee KC, Yuen NW, Lim PL, Chan LY, Tong SF, McCormick F
• ONYX-015: clinical data are encouraging.
  Nature medicine 1998 Kirn D, Hermiston T, McCormick F
• Going for the GAP.
  Current biology : CB 1998 McCormick F
• Akt activation by growth factors is a multiple-step process: the role of the PH domain.
  Oncogene 1998 Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P
• Signal transduction. Why Ras needs Rho.
  Nature 1998 McCormick F
• Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B.
  Science (New York, N.Y.) 1998 Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT
• Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B.
  Science (New York, N.Y.) 1997 Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT
• The superfamily of Ras-related GTPases.
  Japanese journal of cancer research : Gann 1997 McCormick F
• Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation.
  Molecular and cellular biology 1997 Qiu RG, Abo A, McCormick F, Symons M
• ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
  Nature medicine 1997 Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH
• Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in Rat-1 cells.
  The Journal of biological chemistry 1997 Cook SJ, Beltman J, Cadwallader KA, McMahon M, McCormick F
• Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro.
  The EMBO journal 1997 Stokoe D, McCormick F
• The role of p53 in virally associated tumors.
  Trends in microbiology 1997 McCormick F, Wood DA
• Differential regulation of extracellular signal-regulated protein kinase 1 and Jun N-terminal kinase 1 by Ca2+ and protein kinase C in endothelin-stimulated Rat-1 cells.
  The Biochemical journal 1997 Cadwallader K, Beltman J, McCormick F, Cook S
• Signal transduction from multiple Ras effectors.
  Current opinion in genetics & development 1997 Katz ME, McCormick F
• Biochemical characterization of a novel KRAS insertion mutation from a human leukemia.
  The Journal of biological chemistry 1996 Bollag G, Adler F, elMasry N, McCabe PC, Conner E, Thompson P, McCormick F, Shannon K
• Replicating viruses as selective cancer therapeutics.
  Molecular medicine today 1996 Kirn DH, McCormick F
• Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells.
  The Biochemical journal 1996 Cook SJ, McCormick F
• The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase.
  The Journal of biological chemistry 1996 Beltman J, McCormick F, Cook SJ
• An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
  Science (New York, N.Y.) 1996 Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F
• The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades.
  Oncogene 1996 O'Hagan RC, Tozer RG, Symons M, McCormick F, Hassell JA
• Altered transforming growth factor signaling in epithelial cells when ras activation is blocked.
  The Journal of biological chemistry 1996 Hartsough MT, Frey RS, Zipfel PA, Buard A, Cook SJ, McCormick F, Mulder KM
• New molecular targets for cancer therapy.
  Scientific American 1996 Oliff A, Gibbs JB, McCormick F
• Interactions between Ras proteins and their effectors.
  Current opinion in biotechnology 1996 McCormick F, Wittinghofer A
• Ras biology in atomic detail.
  Nature structural biology 1996 McCormick F
• Insulin-induced tyrosine phosphorylation of a M(r) 70,000 protein revealed by association with the Src homology 2 (SH2) and SH3 domains of p120GAP and Grb2.
  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996 Medema JP, Pronk GJ, de Vries-Smits AM, Clark R, McCormick F, Bos JL
• Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1.
  The Journal of biological chemistry 1996 Porfiri E, McCormick F
• Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization.
  Cell 1996 Symons M, Derry JM, Karlak B, Jiang S, Lemahieu V, Mccormick F, Francke U, Abo A
• Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
  Nature genetics 1996 Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K
• The human p62 cDNA encodes Sam68 and not the RasGAP-associated p62 protein.
  Cell 1996 Lock P, Fumagalli S, Polakis P, McCormick F, Courtneidge SA
• A role for Rho in Ras transformation.
  Proceedings of the National Academy of Sciences of the United States of America 1995 Qiu RG, Chen J, McCormick F, Symons M
• Ras-related proteins in signal transduction and growth control.
  Molecular reproduction and development 1995 McCormick F
• Bcr and Raf form a complex in vivo via 14-3-3 proteins.
  The EMBO journal 1995 Braselmann S, McCormick F
• A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20.
  The EMBO journal 1995 Martin GA, Bollag G, McCormick F, Abo A
• Two SH2 domains of p120 Ras GTPase-activating protein bind synergistically to tyrosine phosphorylated p190 Rho GTPase-activating protein.
  The Journal of biological chemistry 1995 Bryant SS, Briggs S, Smithgall TE, Martin GA, McCormick F, Chang JH, Parsons SJ, Jove R
• Rac mediates growth factor-induced arachidonic acid release.
  Cell 1995 Peppelenbosch MP, Qiu RG, de Vries-Smits AM, Tertoolen LG, de Laat SW, McCormick F, Hall A, Symons MH, Bos JL
• The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue.
  Nature 1995 Nassar N, Horn G, Herrmann C, Scherer A, McCormick F, Wittinghofer A
• A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20.
  The EMBO journal 1995 Martin GA, Bollag G, McCormick F, Abo A
• An essential role for Rac in Ras transformation.
  Nature 1995 Qiu RG, Chen J, Kirn D, McCormick F, Symons M
• Ras signaling and NF1.
  Current opinion in genetics & development 1995 McCormick F
• Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays.
  Methods in enzymology 1995 Bollag G, McCormick F
• Purification of recombinant Ras GTPase-activating proteins.
  Methods in enzymology 1995 Bollag G, McCormick F
• Signal transduction by Ras-like GTPases: a potential target for anticancer drugs.
  Gene expression 1995 Spaargaren M, Bischoff JR, McCormick F
• Raf: the holy grail of Ras biology?
  Trends in cell biology 1994 McCormick F
• Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation.
  Science (New York, N.Y.) 1994 Freed E, Symons M, Macdonald SG, McCormick F, Ruggieri R
• From genetics to chemistry: tumor suppressor genes and drug discovery.
  Chemistry & biology 1994 McCormick F, Myers P
• Ras blooms on sterile ground.
  Nature 1994 Cook S, McCormick F
• The Ras-related protein R-ras interacts directly with Raf-1 in a GTP-dependent manner.
  The Biochemical journal 1994 Spaargaren M, Martin GA, McCormick F, Fernandez-Sarabia MJ, Bischoff JR
• Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders.
  The New England journal of medicine 1994 Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F
• Platelet-derived growth factor-induced p21ras-mediated signaling is independent of platelet-derived growth factor receptor interaction with GTPase-activating protein or phosphatidylinositol-3-kinase.
  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994 Burgering BM, Freed E, van der Voorn L, McCormick F, Bos JL
• Activators and effectors of ras p21 proteins.
  Current opinion in genetics & development 1994 McCormick F
• Raf-1 interferes with Ras and Rap1A effector functions in yeast.
  Molecular biology of the cell 1994 Ruggieri R, Macdonald SG, Callow M, McCormick F
• The non-catalytic domain of ras-GAP inhibits transformation induced by G protein coupled receptors.
  Oncogene 1994 Xu N, McCormick F, Gutkind JS
• Analysis of the tumor suppressor activity of the K-rev-1 gene in human tumor cell lines.
  Cancer research 1994 Sato KY, Polakis PG, Haubruck H, Fasching CL, McCormick F, Stanbridge EJ
• Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines.
  Human genetics 1994 Mitsudomi T, Friedman E, Gejman PV, McCormick F, Gazdar AF
• Proteins of the 14-3-3 family associate with Raf and contribute to its activation.
  Cold Spring Harbor symposia on quantitative biology 1994 Freed E, McCormick F, Ruggieri R
• The RAP1GA1 locus for human Rap1-GTPase activating protein 1 maps to chromosome 1p36.1-->p35.
  Cytogenetics and cell genetics 1994 Weiss J, Rubinfeld B, Polakis PG, McCormick F, Cavenee WK, Arden KC
• Proteins regulating Ras and its relatives.
  Nature 1993 Boguski MS, McCormick F
• N-RAS gene activation in acute myeloid leukemia: association with expression of interleukin-6.
  Leukemia 1993 Lübbert M, Oster W, Knopf HP, McCormick F, Mertelsmann R, Herrmann F
• Inhibition by cAMP of Ras-dependent activation of Raf.
  Science (New York, N.Y.) 1993 Cook SJ, McCormick F
• Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours.
  Nature genetics 1993 Friedman E, Gejman PV, Martin GA, McCormick F
• Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro.
  Molecular and cellular biology 1993 Macdonald SG, Crews CM, Wu L, Driller J, Clark R, Erikson RL, McCormick F
• RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts.
  The EMBO journal 1993 Cook SJ, Rubinfeld B, Albert I, McCormick F
• Signal transduction. How receptors turn Ras on.
  Nature 1993 McCormick F
• Structural requirements for the interaction of p21ras with GAP, exchange factors, and its biological effector target.
  The Journal of biological chemistry 1993 Polakis P, McCormick F
• Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity.
  The EMBO journal 1993 Bollag G, McCormick F, Clark R
• Differential regulation of cellular activities by GTPase-activating protein and NF1.
  Molecular and cellular biology 1993 al-Alawi N, Xu G, White R, Clark R, McCormick F, Feramisco JR
• Targets of B lymphocyte antigen receptor signal transduction include the p21ras GTPase-activating protein (GAP) and two GAP-associated proteins.
  Journal of immunology (Baltimore, Md. : 1950) 1993 Gold MR, Crowley MT, Martin GA, McCormick F, DeFranco AL
• The GTPase superfamily. Introduction.
  Ciba Foundation symposium 1993 McCormick F
• Specific changes of Ras GTPase-activating protein (GAP) and a GAP-associated p62 protein during calcium-induced keratinocyte differentiation.
  Molecular and cellular biology 1992 Filvaroff E, Calautti E, McCormick F, Dotto GP
• Interaction between the p21ras GTPase activating protein and the insulin receptor.
  The Journal of biological chemistry 1992 Pronk GJ, Medema RH, Burgering BM, Clark R, McCormick F, Bos JL
• Localization of the rap1GAP catalytic domain and sites of phosphorylation by mutational analysis.
  Molecular and cellular biology 1992 Rubinfeld B, Crosier WJ, Albert I, Conroy L, Clark R, McCormick F, Polakis P
• Functional interaction between p21rap1A and components of the budding pathway in Saccharomyces cerevisiae.
  Molecular and cellular biology 1992 McCabe PC, Haubruck H, Polakis P, McCormick F, Innis MA
• GTPase activating proteins.
  Seminars in cancer biology 1992 Bollag G, McCormick F
• GTPase-activating protein SH2-SH3 domains induce gene expression in a Ras-dependent fashion.
  Molecular and cellular biology 1992 Medema RH, de Laat WL, Martin GA, McCormick F, Bos JL
• Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications.
  World journal of surgery 1992 Goretzki PE, Lyons J, Stacy-Phipps S, Rosenau W, Demeure M, Clark OH, McCormick F, Röher HD, Bourne HR
• Phosphorylation of rap1GAP in vivo and by cAMP-dependent kinase and the cell cycle p34cdc2 kinase in vitro.
  The Journal of biological chemistry 1992 Polakis P, Rubinfeld B, McCormick F
• Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways.
  Cell 1992 Fantl WJ, Escobedo JA, Martin GA, Turck CW, del Rosario M, McCormick F, Williams LT
• Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62.
  Cell 1992 Wong G, Müller O, Clark R, Conroy L, Moran MF, Polakis P, McCormick F
• Coupling of ras p21 signalling and GTP hydrolysis by GTPase activating proteins.
  Philosophical transactions of the Royal Society of London. Series B, Biological sciences 1992 McCormick F
• Ras regulation. NF is enough of GAP.
  Nature 1992 Bollag G, McCormick F
• p21rasGAP association with Fyn, Lyn, and Yes in thrombin-activated platelets.
  The Journal of biological chemistry 1992 Cichowski K, McCormick F, Brugge JS
• Association of a tyrosine kinase activity with GAP complexes in v-src transformed fibroblasts.
  Oncogene 1992 Pronk GJ, Polakis P, Wong G, de Vries-Smits AM, Bos JL, McCormick F
• Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
  Oncogene 1992 Lübbert M, Mirro J, Kitchingman G, McCormick F, Mertelsmann R, Herrmann F, Koeffler HP
• GAP domains responsible for ras p21-dependent inhibition of muscarinic atrial K+ channel currents.
  Science (New York, N.Y.) 1992 Martin GA, Yatani A, Clark R, Conroy L, Polakis P, Brown AM, McCormick F
• Interactions between p21ras proteins and their GTPase activating proteins.
  Cancer surveys 1992 Polakis P, McCormick F
• Heterogeneous amino acids in Ras and Rap1A specifying sensitivity to GAP proteins.
  Science (New York, N.Y.) 1991 Zhang K, Papageorge AG, Martin P, Vass WC, Olah Z, Polakis PG, McCormick F, Lowy DR
• Ras p21: effects and regulation.
  Biochimica et biophysica acta 1991 Haubruck H, McCormick F
• Role of GTPase activating protein in mitogenic signalling through phosphatidylcholine-hydrolysing phospholipase C.
  The EMBO journal 1991 Dominguez I, Marshall MS, Gibbs JB, García de Herreros A, Cornet ME, Graziani G, Diaz-Meco MT, Johansen T, McCormick F, Moscat J
• Ras and the awd couple.
  Nature 1991 Ruggieri R, McCormick F
• A synthetic peptide corresponding to a sequence in the GTPase activating protein inhibits p21ras stimulation and promotes guanine nucleotide exchange.
  International journal of peptide and protein research 1991 Rubinfeld B, Wong G, Bekesi E, Wood A, Heimer E, McCormick F, Polakis P
• Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.
  Proceedings of the National Academy of Sciences of the United States of America 1991 Pendergast AM, Muller AJ, Havlik MH, Clark R, McCormick F, Witte ON
• Molecular cloning of a GTPase activating protein specific for the Krev-1 protein p21rap1.
  Cell 1991 Rubinfeld B, Munemitsu S, Clark R, Conroy L, Watt K, Crosier WJ, McCormick F, Polakis P
• Differential regulation of rasGAP and neurofibromatosis gene product activities.
  Nature 1991 Bollag G, McCormick F
• GTP-binding proteins as oncogenes in human tumors.
  Environmental health perspectives 1991 McCormick F
• Insulin stimulation of gene expression mediated by p21ras activation.
  The EMBO journal 1991 Burgering BM, Medema RH, Maassen JA, van de Wetering ML, van der Eb AJ, McCormick F, Bos JL
• Regulation of Ras-GAP and the neurofibromatosis-1 gene product by eicosanoids.
  Science (New York, N.Y.) 1991 Han JW, McCormick F, Macara IG
• Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein.
  Molecular and cellular biology 1991 Moran MF, Polakis P, McCormick F, Pawson T, Ellis C
• The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein.
  Molecular and cellular biology 1991 Buss JE, Quilliam LA, Kato K, Casey PJ, Solski PA, Wong G, Clark R, McCormick F, Bokoch GM, Der CJ
• The GTPase superfamily: conserved structure and molecular mechanism.
  Nature 1991 Bourne HR, Sanders DA, McCormick F
• Purification of a plasma membrane-associated GTPase-activating protein specific for rap1/Krev-1 from HL60 cells.
  Proceedings of the National Academy of Sciences of the United States of America 1991 Polakis PG, Rubinfeld B, Evans T, McCormick F
• Regulation of ras p21 by GTPase activating proteins.
  Cold Spring Harbor symposia on quantitative biology 1991 McCormick F, Martin GA, Clark R, Bollag G, Polakis P
• Regulators and effectors of ras proteins.
  Annual review of cell biology 1991 Bollag G, McCormick F
• Purification, characterization, and western blot analysis of human GTPase-activating protein from native and recombinant sources.
  The Journal of biological chemistry 1990 Halenbeck R, Crosier WJ, Clark R, McCormick F, Koths K
• Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein.
  The Journal of clinical endocrinology and metabolism 1990 Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR
• The GTPase superfamily: a conserved switch for diverse cell functions.
  Nature 1990 Bourne HR, Sanders DA, McCormick F
• Molecular cloning and expression of a G25K cDNA, the human homolog of the yeast cell cycle gene CDC42.
  Molecular and cellular biology 1990 Munemitsu S, Innis MA, Clark R, McCormick F, Ullrich A, Polakis P
• Oncogenes in multiple myeloma: point mutation of N-ras.
  Oncogene 1990 Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP
• The world according to GAP.
  Oncogene 1990 McCormick F
• Suppression of c-ras transformation by GTPase-activating protein.
  Nature 1990 Zhang K, DeClue JE, Vass WC, Papageorge AG, McCormick F, Lowy DR
• Inhibition of GTPase activating protein stimulation of Ras-p21 GTPase by the Krev-1 gene product.
  Science (New York, N.Y.) 1990 Frech M, John J, Pizon V, Chardin P, Tavitian A, Clark R, McCormick F, Wittinghofer A
• Biochemical characterization of baculovirus-expressed rap1A/Krev-1 and its regulation by GTPase-activating proteins.
  Molecular and cellular biology 1990 Quilliam LA, Der CJ, Clark R, O'Rourke EC, Zhang K, McCormick F, Bokoch GM
• ras p21 and GAP inhibit coupling of muscarinic receptors to atrial K+ channels.
  Cell 1990 Yatani A, Okabe K, Polakis P, Halenbeck R, McCormick F, Brown AM
• PDGF beta-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex.
  Cell 1990 Kaplan DR, Morrison DK, Wong G, McCormick F, Williams LT
• GTP binding and growth control.
  Current opinion in cell biology 1990 McCormick F
• Retrospective analysis of ras gene activation in myeloid leukemic cells.
  Oncogene 1990 Lübbert M, Jonas D, Miller CW, Herrmann F, Mertelsmann R, McCormick F, Koeffler HP
• N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.
  Blood 1990 Lübbert M, Mirro J, Miller CW, Kahan J, Isaac G, Kitchingman G, Mertelsmann R, Herrmann F, McCormick F, Koeffler HP
• RAS mutations in patients following cytotoxic therapy for lymphoma.
  Oncogene 1990 Carter G, Hughes DC, Clark RE, McCormick F, Jacobs A, Whittaker JA, Padua RA
• Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.
  Nature 1990 Ellis C, Moran M, McCormick F, Pawson T
• GAP as ras effector or negative regulator?
  Molecular carcinogenesis 1990 McCormick F
• Genetic analysis of mammalian GAP expressed in yeast.
  Cell 1989 Ballester R, Michaeli T, Ferguson K, Xu HP, McCormick F, Wigler M
• Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells.
  Cancer research 1989 Valverius EM, Walker-Jones D, Bates SE, Stampfer MR, Clark R, McCormick F, Dickson RB, Lippman ME
• Gasp: not just another oncogene.
  Nature 1989 McCormick F
• Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells.
  Cancer research 1989 Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, McCormick F, Stampfer M, Abularach S, Gelmann EP
• Human bladder and colon carcinomas contain activated ras p21. Specific detection of twelfth codon mutants.
  Cancer 1989 Meyers FJ, Gumerlock PH, Kokoris SP, deVere White RW, McCormick F
• Identification of resonances from an oncogenic activating locus of human N-RAS-encoded p21 protein using isotope-edited NMR.
  Proceedings of the National Academy of Sciences of the United States of America 1989 Burk SC, Papastavros MZ, McCormick F, Redfield AG
• ras GTPase activating protein: signal transmitter and signal terminator.
  Cell 1989 McCormick F
• Analysis of RAS oncogene mutations in human lymphoid malignancies.
  Proceedings of the National Academy of Sciences of the United States of America 1988 Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R
• Transformation of human mammary epithelial cells by oncogenic retroviruses.
  Cancer research 1988 Clark R, Stampfer MR, Milley R, O'Rourke E, Walen KH, Kriegler M, Kopplin J, McCormick F
• RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.
  Leukemia 1988 Padua RA, Carter G, Hughes D, Gow J, Farr C, Oscier D, McCormick F, Jacobs A
• Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain.
  Science (New York, N.Y.) 1988 Adari H, Lowy DR, Willumsen BM, Der CJ, McCormick F
• Functional properties of proteins coded by three human alpha-interferon genes and a pseudogene.
  Cancer research 1988 Creasey AA, Vitt CR, Herst C, O'Rourke E, Doyle L, Innis MA, McCabe PC, McCormick F, Milley R, Lin LS
• Interaction of ras p21 proteins with GTPase activating protein.
  Cold Spring Harbor symposia on quantitative biology 1988 McCormick F, Adari H, Trahey M, Halenbeck R, Koths K, Martin GA, Crosier WJ, Watt K, Rubinfeld B, Wong G
• A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.
  Science (New York, N.Y.) 1987 Trahey M, McCormick F
• Biochemical and biological properties of the human N-ras p21 protein.
  Molecular and cellular biology 1987 Trahey M, Milley RJ, Cole GE, Innis M, Paterson H, Marshall CJ, Hall A, McCormick F
• Inhibition of cell surface ruffling and fluid-phase pinocytosis by microinjection of anti-ras antibodies into living cells.
  Journal of cellular physiology. Supplement 1987 Bar-Sagi D, McCormick F, Milley RJ, Feramisco JR
• Detection of activated Mr 21,000 protein, the product of ras oncogenes, using antibodies with specificity for amino acid 12.
  Cancer research 1986 Wong G, Arnheim N, Clark R, McCabe P, Innis M, Aldwin L, Nitecki D, McCormick F
• Genetic and biochemical analysis of ras p21 structure.
  Symposium on Fundamental Cancer Research 1986 McCormick F, Levenson C, Cole G, Innis M, Clark R
• Procedures for expression, modification, and analysis of human fibroblast interferon (IFN-beta) genes in heterologous cells.
  Methods in enzymology 1986 Innis MA, McCormick F
• Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding.
  Proceedings of the National Academy of Sciences of the United States of America 1985 Clark R, Wong G, Arnheim N, Nitecki D, McCormick F
• Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein.
  Nature 1985 Feramisco JR, Clark R, Wong G, Arnheim N, Milley R, McCormick F
• Inhibition of protein synthesis stimulates the transcription of human beta-interferon genes in Chinese hamster ovary cells.
  Proceedings of the National Academy of Sciences of the United States of America 1984 Ringold GM, Dieckmann B, Vannice JL, Trahey M, McCormick F
• Inducible expression of amplified human beta interferon genes in CHO cells.
  Molecular and cellular biology 1984 McCormick F, Trahey M, Innis M, Dieckmann B, Ringold G
• SV40 T antigen binds specifically to a cellular 53 K protein in vitro.
  Nature 1981 McCormick F, Clark R, Harlow E, Tjian R
• Association of a murine 53,000-dalton phosphoprotein with simian virus 40 large-T antigen in transformed cells.
  Journal of virology 1980 McCormick F, Harlow E
• T antigens of SV40-transformed cells.
  Cold Spring Harbor symposia on quantitative biology 1980 McCormick F, Chaudry F, Harvey R, Smith R, Rigby PW, Paucha E, Smith AE
• Kinetics of polyamine synthesis and turnover in mouse fibroblasts.
  The Biochemical journal 1978 McCormick F